BLAINJECTIONINJECTABLE
Approved
Aug 2023
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
3/8 — Basic
TYRUKO (natalizumab-sztn) by Novartis is integrin receptor antagonists [moa]. Approved for integrin receptor antagonist [epc]. First approved in 2023.
Drug data last refreshed 16h ago · AI intelligence enriched 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TYRUKO (natalizumab-sztn) is a monoclonal antibody integrin receptor antagonist approved in August 2023 as a biosimilar to Tysabri. It blocks integrin-mediated cell adhesion to treat inflammatory conditions by preventing leukocyte migration into affected tissues.
Growth
Newly approved biosimilar in growth phase with significant market penetration opportunity against established reference product; expect expanding sales team and medical affairs infrastructure.
Mechanism of Action
Integrin Receptor Antagonists
Pharmacologic Class:
Integrin Receptor Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on TYRUKO positions you in the high-growth biosimilar segment where value is created through market penetration, payer negotiations, and interchangeability advocacy rather than clinical innovation. This role suits professionals focused on commercial execution, market access strategy, and value-based selling in a competitive biologics environment.
Brand Manager
Worked on TYRUKO at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.